Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)

The "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer" is a grant opportunity that does not allow for clinical trials. This funding initiative aims to back preliminary or formative research pertaining to basic scientific concepts that illustrate how the human microbiome can either obstruct or magnify anti-tumor immune responses. The goal is to uncover potential new molecular targets that can be utilized for cancer prevention strategies.

Applicants should focus their submissions on determining how the host interacts with specific microbes (or groups of microbes) or their metabolic by-products. These should aim at the manipulation of immune responses in order to augment or prevent inflammation-related or irregular tumor formation.

Attention should be given to the degree, scheduling, and span of administered beneficial microbes, as these factors can significantly influence its effectiveness. The grant application should demonstratively address these parameters.